Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid and Vidaza Maintenance Therapy in Elderly AML Patients
NCT01301820Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Jan 2011
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, lenalidomide in acute myeloid leukemia (AML), sponsored by French Innovative Leukemia Organisation. Started Jan 2011; status: completed.
02
Drugs
azacitidinelenalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01301820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301820.